SuperworthAquestive Therapeutics AQST
- Market cap
- $502M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 9.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $54.1M
- +23% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −9.2%
Aquestive Therapeutics trades at 9.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $54.1M over the last twelve months, up 23% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13M+13% | $13.2M+24% | $12.1M+8% | $20.1M+52% | $13.5M+4% | $11.9M−10% | $8.7M−28% | $10M−50% | $12.8M−5% | $13M+10% | $14.4M+66% | $13.8M+38% | |
| Cost of revenue | $4.8M+4% | $4.7M−12% | $4.4M−7% | $4.5M−32% | $4.4M−8% | $4.5M−3% | $3.7M−17% | $4.6M+1% | $4.5M+2% | $5.8M+29% | $3.5M−5% | $4M−12% |
| Gross profit | $8.2M+20% | $8.5M+59% | $7.7M+20% | $15.6M+135% | $9.1M+11% | $7.3M−14% | $5.1M−34% | $5.4M−65% | $8.3M−9% | $7.2M−2% | $11M+117% | $9.8M+80% |
| R&D | $3.2M−1% | $2.9M−33% | $5.9M+67% | $4.2M+20% | $5.3M+65% | $4.9M+70% | $5.4M−10% | $4.1M−1% | $4.5M−14% | $3.2M−35% | $4.2M−22% | $4M−4% |
| SG&A | $7.4M−41% | $9.6M−19% | $10.7M+43% | $11.4M+54% | $12.1M+64% | $16M+68% | $19.1M+78% | $12.7M+12% | $15.3M+26% | $32.8M+105% | $11M−42% | $14.1M+11% |
| −$2.4M−73% | −$3.9M−64% | −$9M+95% | $55K | −$8.3M+249% | −$13.6M+247% | −$19.4M+116% | −$11.4M | −$11.5M+39% | −$28.8M+112% | −$4.2M−78% | −$8.2M−28% | |
| Interest expense | $1.3M−24% | $2.3M+38% | $2.8M+94% | $2.8M+102% | $2.8M+121% | $2.8M+22% | $2.8M−0% | $2.8M+0% | $2.8M+0% | $2.8M+0% | $2.9M+4% | $2.8M+1% |
| Pre-tax income | −$2.2M−83% | −$8M−35% | −$12.8M | −$2.7M−50% | −$11.5M+429% | −$17.1M+113% | −$22.9M+79% | −$13.5M+394% | −$15.4M+34% | −$31.9M+87% | −$8.1M−65% | −$22.9M+69% |
| −$140K | $101K | $0 | $0 | $0 | −$14K | $0 | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$2M−84% | −$8.1M−34% | −$12.8M | −$2.7M−53% | −$11.5M+466% | −$17.1M+110% | −$22.9M+79% | −$13.5M+394% | −$15.4M+34% | −$31.9M+87% | −$8.1M−65% | −$22.9M+69% |
| −$0.03−87% | −$0.12−48% | −$0.17 | −$0.03−70% | −$0.13+333% | −$0.19+58% | −$0.24+41% | −$0.14+367% | −$0.14+8% | −$0.26+37% | −$0.07−71% | −$0.18+29% | |
| 64.7M+21% | 67.2M+24% | 73.6M−0% | 90.9M+59% | 91.1M+41% | 91.2M+36% | 95.5M+30% | 99.3M+9% | 110.6M+21% | 122M+34% | 122.6M+28% | 125M+26% |
Revenue: Q1 FY18: 6 months less the 3 months printed beside them.
Gross profit: 29 periods, Q1 FY19 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Aquestive Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AQSTAquestive Therapeutics | $502M | n/m | n/a | 9.3× | +23% | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Aquestive Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .